Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GMAB | Copenhagen | DKK | Real-time | |
GMABc | BATS Europe | DKK | Delayed | |
GMAB | NASDAQ | USD | Real-time | |
0MGB | London | DKK | Real-time | |
GMAB | Vienna | EUR | Real-time |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Copenhagen | 1,976.0 | 0.0 | 0.0 | 8,767 | -0.93% | DKK | |||
BATS Europe | 1,994.00 | 1,974.00 | 2,014.00 | 0 | 0.00% | DKK | |||
NASDAQ | 28.33 | 28.00 | 28.74 | 242,491 | -0.70% | USD | |||
London | 1,975.50 | 1,942.50 | 2,029.00 | 446 | -1.05% | DKK | |||
Vienna | 266.00 | 262.80 | 266.00 | 0 | +0.00% | EUR |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 165.80 | 166.25 | 162.15 | -4.00 | -2.36% | 2.97M | 08:21:36 | ||
EasyJet | 519.95 | 529.00 | 516.33 | -10.05 | -1.90% | 328.80K | 08:21:48 | ||
Rolls-Royce Holdings | 396.14 | 399.00 | 394.60 | -6.36 | -1.58% | 889.60K | 08:21:48 | ||
Lloyds Banking | 50.52 | 50.83 | 50.28 | -0.48 | -0.94% | 6.25M | 08:21:56 | ||
BP | 512.50 | 514.40 | 510.50 | +0.10 | +0.02% | 1.60M | 08:21:56 | ||
Ocado | 345.46 | 346.90 | 343.00 | -4.54 | -1.30% | 50.52K | 08:21:26 | ||
Centamin | 127.50 | 128.40 | 127.00 | -0.60 | -0.47% | 285.98K | 08:21:01 | ||
Barclays | 182.50 | 182.90 | 181.70 | -1.48 | -0.80% | 2.61M | 08:21:49 | ||
BAE Systems | 1,284.00 | 1,290.00 | 1,280.50 | -3.00 | -0.23% | 352.40K | 08:21:57 | ||
HSBC | 636.00 | 636.90 | 633.80 | -8.60 | -1.33% | 1.31M | 08:21:30 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review